Dobutamine administration in patients after cardiac surgery: beneficial or harmful?

We read with interest the article by Shahin and colleagues [1] in the previous issue of Critical Care. Th e authors suggested, in a retrospective analysis, that dobutamine use in patients undergoing cardiac surgery was independently associated with a 2.3-fold increase in mortality and a 2.7-fold increase in risk of renal dysfunction. We have some concerns regarding this conclusion. Th e primary concern with this analysis is the choice of covariates included in the multivariable logistic regression. Th ese were not derived from a univariate analysis. Also, co-variates included in the logistic regression were diff erent from variables used in the matching propensity analysis. In the matching analysis, the ejection fraction (EF) in the group exposed to dobutamine was signifi cantly lower than the EF in the other patients, and this may have contributed to worse outcomes. So, these potential biases are of concern, especially when we consider that these results are inconsistent with the daily routine practice of cardiac surgery in many centers. In a recent commentary, Singer and Brealey [2] argued that, other than dobutamine, current options to improve the hemodynamic status of critically ill patients are relatively limited. After cardiac surgery, this is even more true, as the vasodilation frequently present in these patients can limit the use of other inodilators like levosimendan and milrinone [3]. Pharmacological support for low cardiac output is often required during and after weaning from cardiopulmonary bypass [4]. During this early postoperative period, optimization of cardiac output is needed to prevent complications, and dobutamine is the drug of choice because of its good tolerance and safety [5]. New agents are being evaluated, but dobutamine is still the inotropic of choice in patients undergoing cardiac surgery [4]. Although this study suggests that dobutamine may increase morbidity and mortality after cardiac surgery [1], there is no reason to ban dobutamine after cardiac surgery, as it may still be more benefi cial than harmful.

We read with interest the article by Shahin and colleagues [1] in the previous issue of Critical Care. Th e authors suggested, in a retrospective analysis, that dobutamine use in patients undergoing cardiac surgery was independently associated with a 2.3-fold increase in mortality and a 2.7-fold increase in risk of renal dysfunction. We have some concerns regarding this conclusion. Th e primary concern with this analysis is the choice of covariates included in the multivariable logistic regression. Th ese were not derived from a univariate analysis. Also, co-variates included in the logistic regression were diff erent from variables used in the matching propensity analysis. In the matching analysis, the ejection fraction (EF) in the group exposed to dobutamine was significantly lower than the EF in the other patients, and this may have contributed to worse outcomes. So, these potential biases are of concern, especially when we consider that these results are inconsistent with the daily routine practice of cardiac surgery in many centers.
In a recent commentary, Singer and Brealey [2] argued that, other than dobutamine, current options to improve the hemodynamic status of critically ill patients are relatively limited. After cardiac surgery, this is even more true, as the vasodilation frequently present in these patients can limit the use of other inodilators like levosimendan and milrinone [3]. Pharmacological support for low cardiac output is often required during and after weaning from cardiopulmonary bypass [4]. During this early postoperative period, optimization of cardiac output is needed to prevent complications, and dobutamine is the drug of choice because of its good tolerance and safety [5].
New agents are being evaluated, but dobutamine is still the inotropic of choice in patients undergoing cardiac surgery [4]. Although this study suggests that dobutamine may increase morbidity and mortality after cardiac surgery [1], there is no reason to ban dobutamine after cardiac surgery, as it may still be more benefi cial than harmful.

Jason Shahin
We thank Hajjar and colleagues for their interest in our article examining the association between inotrope exposure and poor outcomes in a cardiac surgery population. In regard to the choice of co-variates in the multivariable model, we choose to include variables that were known a priori (that is, on the basis of previous literature and clinical expertise) to have an association with mortality and renal failure. We have concerns with the common practice of choosing co-variates on the basis of univariable analysis, as the potential for bias exists [6]. Specifi cally, variables can be inappropriately excluded from a model if the prespecifi ed P value is not met in univariable analysis. As univariable analysis does not account for confounding, variables may be inappropriately excluded, leading to errors in the model [7].
With reference to the EF in the matched analysis, we agree that there were small diff erences in the mean EF. However, given that there was a similar proportion of patients with an EF of less than 30% ( Table 5 in [1]), the potential for bias is minimal. Th is diff erence is unlikely to account for the observed asso ciation between inotrope exposure and mortality.
We also agree that there is no reason to 'ban dobutamine after cardiac surgery' , as it is an important medication in our clinical armamentarium. Our data did not suggest that one inotrope was worse than the other. In fact, only 14% of admissions in the inotrope-exposed group received postoperative dobutamine. Rather than a *Correspondence: ludhmila@usp.br Surgical Intensive Care Unit, InCor, Heart Institute, University of Sao Paulo, Avenida Dr Eneas de Carvalho Aguiar no. 44, ZIP 05403-000, Sao Paulo, SP Brazil